AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease

AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease

Shots:

  • The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9,000+ patients with anemia + CKD not on dialysis (NDD) , dialysis-dependent (DD), ID respectively
  • Pooled analyses results: MACE/MACE+ in NDD & DD patients, clinically no difference; MACE/MACE+ in ID patients shows better results
  • Roxadustat is hypoxia-inducible-factor prolyl hydroxylase inhibitor, evaluated under the collaboration of AstraZeneca, FibroGen and Astellas with its expected FDA’s regulatory submission in H2’19

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter